{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:54:53Z","timestamp":1789750493278,"version":"4.0.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Immune checkpoints are small molecules present on the cell surface of T-lymphocytes. They maintain self-tolerance and regulate the amplitude and duration of T-cell responses. Antagonism of immune checkpoints with monoclonal antibodies (immune checkpoint inhibitors) is a rapidly evolving field of anti-cancer immunotherapy and has become standard of care in management of many cancer subtypes. Immune checkpoint inhibition is an effective cancer treatment but can precipitate immune related adverse events (irAEs). Thyroid dysfunction is the most common endocrine irAE and can occur in up to 40% of treated patients. Both thyrotoxicosis and hypothyroidism occur. The clinical presentation and demographic associations of thyrotoxicosis compared to hypothyroidism suggest unique entities with different etiologies. Thyroid irAEs, particularly overt thyrotoxicosis, are associated with increased immune toxicity in other organ systems, but also with longer progression-free and overall survival. Polygenic risk scores using susceptibility loci associated with autoimmune thyroiditis predict development of checkpoint inhibitor associated irAEs, suggesting potentially shared mechanisms underpinning their development. Our review will provide an up-to-date summary of knowledge in the field of thyroid irAEs. Major focus will be directed toward pathogenesis (including genetic factors shared with autoimmune thyroid disease), demographic associations, clinical presentation and course, treatment, and the relationship with cancer outcomes.<\/jats:p>","DOI":"10.3389\/fendo.2022.886930","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T01:57:04Z","timestamp":1653530224000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":53,"title":["Immune Related Adverse Events of the Thyroid \u2013 A Narrative Review"],"prefix":"10.3389","volume":"13","author":[{"given":"Christopher A.","family":"Muir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venessa H. M.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roderick J.","family":"Clifton-Bligh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1056\/NEJMp2116863","article-title":"The Wild West of Checkpoint Inhibitor Development","volume":"386","author":"Beaver","year":"2021","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated With Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"New Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-Related Adverse Events of Checkpoint Inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3239","article-title":"The Blockade of Immune Checkpoints in Cancer Immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41573-021-00345-8","article-title":"The Foundations of Immune Checkpoint Blockade and the Ipilimumab Approval Decennial","author":"Korman","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr Rev"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0032","article-title":"Thyroid Toxicity Following Immune Checkpoint Inhibitor Treatment in Advanced Cancer","volume":"30","author":"Muir","year":"2020","journal-title":"Thyroid"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1111\/cen.13297","article-title":"Thyroid Abnormalities Following the Use of Cytotoxic T-Lymphocyte Antigen-4 and Programmed Death Receptor Protein-1 Inhibitors in the Treatment of Melanoma","volume":"86","author":"Morganstein","year":"2017","journal-title":"Clin Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-0810","article-title":"The Spectrum, Incidence, Kinetics and Management of Endocrinopathies With Immune Checkpoint Inhibitors for Metastatic Melanoma","volume":"178","author":"Scott","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0472","article-title":"Baseline Tsh Level Is Associated With Risk of Anti-Pd-1-Induced Thyroid Dysfunction","volume":"25","author":"Pollack","year":"2019","journal-title":"Endocr Pract"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgab263","article-title":"Thyroid Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Treatment","volume":"106","author":"Muir","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-022-03151-2","article-title":"Divergent Prognostic Effects of Pre-Existing and Treatment-Emergent Thyroid Dysfunction in Patients Treated With Immune Checkpoint Inhibitors","author":"von Itzstein","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-Related Thyroiditis With Immune Checkpoint Inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac059","article-title":"Association of Anti-Thyroid Antibodies in Checkpoint Inhibitor Associated Thyroid Immune Related Adverse Events","volume":"107","author":"Muir","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01871-7","article-title":"Thyroid Dysfunction Induced by Nivolumab: Searching for Disease Patterns and Outcomes","volume":"64","author":"Peiro","year":"2019","journal-title":"Endocrine"},{"key":"B16","doi-asserted-by":"publisher","first-page":"413","DOI":"10.3803\/EnM.2020.906","article-title":"Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated With PD-1\/PD-L1 Inhibitors","volume":"36","author":"Yoon","year":"2021","journal-title":"Endocrinol Metab"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa458","article-title":"Immune Checkpoint Inhibitor-Induced Thyroid Dysfunction Is Associated With Higher Body Mass Index","volume":"105","author":"Pollack","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13800","article-title":"Association of Antithyroglobulin Antibodies With the Development of Thyroid Dysfunction Induced by Nivolumab","volume":"109","author":"Kimbara","year":"2018","journal-title":"Cancer Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/cas.14363","article-title":"Predictive and Sensitive Biomarkers for Thyroid Dysfunctions During Treatment With Immune-Checkpoint Inhibitors","volume":"111","author":"Kurimoto","year":"2020","journal-title":"Cancer Sci"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41591-021-01623-z","article-title":"T Cell Characteristics Associated With Toxicity to Immune Checkpoint Blockade in Patients With Melanoma","volume":"28","author":"Lozano","year":"2022","journal-title":"Nat Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41467-021-23661-4","article-title":"Genetic Variation Associated With Thyroid Autoimmunity Shapes the Systemic Immune Response to PD-1 Checkpoint Blockade","volume":"12","author":"Khan","year":"2021","journal-title":"Nat Commun"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-0921","article-title":"Immunotherapy-Mediated Thyroid Dysfunction: Genetic Risk and Impact on Outcomes With PD-1 Blockade in Non\u2013Small Cell Lung Cancer","volume":"27","author":"Luo","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"102285","DOI":"10.1016\/j.jaut.2019.05.013","article-title":"Analysis of the PD-1\/PD-L1 Axis in Human Autoimmune Thyroid Disease: Insights Into Pathogenesis and Clues to Immunotherapy Associated Thyroid Autoimmunity","volume":"103","author":"lvarez-Sierra","year":"2019","journal-title":"J Autoimmun"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2020.0075","article-title":"Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated With Increased Intrathyroidal T Lymphocyte Subpopulations","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2021.0685","article-title":"Optimal Thyroid Hormone Replacement Dose in Immune Checkpoint Inhibitor-Associated Hypothyroidism Is Distinct From Hashimoto\u2019s Thyroiditis","author":"Mosaferi","year":"2022","journal-title":"Thyroid"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0375","article-title":"Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune-Checkpoint Inhibitors for Cancer Treatment","volume":"23","author":"Patel","year":"2018","journal-title":"Oncologist"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-10-0833","article-title":"Thyroid Autoimmunity and Ophthalmopathy Related to Melanoma Biological Therapy","volume":"164","author":"Min","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non\u2013Small-Cell Lung Cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.633032","article-title":"Association of Immune Related Adverse Events With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-Analysis","volume":"11","author":"Fan","year":"2021","journal-title":"Front Oncol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00262-021-03128-7","article-title":"Associations Between Immune-Related Thyroid Dysfunction and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis","author":"Cheung","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000664","article-title":"Survival Benefit of Endocrine Dysfunction Following Immune Checkpoint Inhibitors for Nonthyroidal Cancers","volume":"28","author":"Kotwal","year":"2021","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"B33","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","article-title":"Improved Survival in Patients With Thyroid Function Test Abnormalities Secondary to Immune-Checkpoint Inhibitors","volume":"70","author":"Ferreira","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0250","article-title":"PD-L1 Inhibitor-Induced Thyroiditis is Associated With Better Overall Survival in Cancer Patients","volume":"30","author":"Kotwal","year":"2020","journal-title":"Thyroid"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0726","article-title":"Overt Thyroid Dysfunction and Anti-Thyroid Antibodies Predict Response to Anti-PD-1 Immunotherapy in Cancer Patients","volume":"30","author":"Basak","year":"2020","journal-title":"Thyroid"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0216954","article-title":"Incidence, Features, and Prognosis of Immune-Related Adverse Events Involving the Thyroid Gland Induced by Nivolumab","volume":"14","author":"Yamauchi","year":"2019","journal-title":"PloS One"},{"key":"B37","doi-asserted-by":"publisher","first-page":"EJ20","DOI":"10.1507\/endocrj.EJ20-0371","article-title":"Distinct Clinical Features and Prognosis Between Persistent and Temporary Thyroid Dysfunctions by Immune-Checkpoint Inhibitors","author":"Inaba","year":"2020","journal-title":"Endocr J"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.5860","article-title":"Profiling Preexisting Antibodies in Patients Treated With Anti\u2013PD-1 Therapy for Advanced Non\u2013Small Cell Lung Cancer","volume":"5","author":"Toi","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.886930\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T01:57:06Z","timestamp":1653530226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2022.886930\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":38,"alternative-id":["10.3389\/fendo.2022.886930"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2022.886930","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"article-number":"886930"}}